Crohn's Disease: Eight-Market Drug Forecast and Market Analysis

List of Tables

This report covers the 8 major markets and provides an Excel-based forecast model for the Crohn's Disease market through 2032.

GlobalData estimates CD drug sales across the 8MM covered in this report will increase from $9.5 billion to $13.8 billion, at a compound annual growth rate (CAGR) of 3.9%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 8 pipeline, generic, and biosimilar therapies.

Scope

Overview of Crohn's Disease (CD), including epidemiology, symptoms, diagnosis, and disease management.
Annualized Crohn's Disease (CD) therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the CD therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for CD treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Crohn's Disease (CD) therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 8MM Crohn's Disease (CD) therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Crohn's Disease (CD) therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC335PIDR-8M

List of Tables

List of Figures

1 Crohn's Disease: Executive Summary

1.1 Summary of changes
1.2 Steady growth is expected for the CD market from 2022-32
1.3 Novel MOAs will provide market shifts throughout the forecast period
1.4 Lack of tools to properly treat patients with CD is a clear unmet need within the market
1.5 Pipeline Drugs
1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.1.3 CD Classification

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 8MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
4.5 Epidemiological forecast for Crohn's disease (2022-32)
- 4.5.1 Diagnosed incident cases of CD
- 4.5.2 Age-specific diagnosed incident cases of CD
- 4.5.3 Sex-specific diagnosed incident cases of CD
- 4.5.4 Diagnosed prevalent cases of CD
- 4.5.5 Age-specific diagnosed prevalent cases of CD
- 4.5.6 Sex-specific diagnosed prevalent cases of CD
- 4.5.7 Diagnosed prevalent cases of CD by severity
- 4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
- 4.5.9 Diagnosed prevalent cases of CD in remission by severity
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
7.4 Improved Medical Management of Perianal Fistulas
7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

8.1 Overview
- 8.1.1 Novel MOAs
- 8.1.2 Biomarkers
8.2 Clinical Trials Design
- 8.2.1 Patient inclusion criteria
- 8.2.2 Endpoints

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key Events
- 12.4.3 Drivers and barriers
12.5 Canada
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
- 13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Managing Analyst
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers
- 13.6.5 Global Director of Therapy Analysis and Epidemiology
About GlobalData
Contact Us

Product Code: GDHC335PIDR-8M

List of Table

List of Tables

Table 1: CD: Key metrics in the 8MM
Table 2: Summary of changes to CD Eight-Market Drug Forecast and Analysis to 2032
Table 3: Crohn's disease severities
Table 4: Risk factors and comorbidities for CD
Table 5: Treatment guidelines for CD
Table 6: Top 10 deals by value, 2018-2024
Table 7: CD market - global drivers and barriers, 2022-32
Table 8: Key events impacting sales for CD in the US, 2022-32
Table 9: CD market - drivers and barriers in the US, 2022-32
Table 10: Key events impacting sales for CD in the 5EU, 2022-32
Table 11: CD market - drivers and barriers in the 5EU, 2022-32
Table 12: Key events impacting sales for CD in Japan, 2022-32
Table 13: CD market - drivers and barriers in Japan, 2022-32
Table 14: Key events impacting sales for CD in Canada, 2022-32
Table 15: CD market - drivers and barriers in Canada, 2022-32
Table 16: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for CD in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in CD during the forecast period
Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira
Figure 4: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
Figure 5: Pathophysiology of Crohn's disease
Figure 6: 8MM, diagnosed incidence of CD, men and women, cases per 100,000 population, all ages, 2022
Figure 7: 8MM, diagnosed prevalence of CD, men and women, %, all ages, 2022
Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of CD
Figure 9: 8MM, sources used and not used to forecast the diagnosed prevalent cases of CD
Figure 10: 8MM, diagnosed incident cases of CD, N, both sexes, all ages, 2022
Figure 11: 8MM, diagnosed incident cases of CD by age, N, both sexes, 2022
Figure 12: 8MM, diagnosed incident cases of CD by sex, N, all ages, 2022
Figure 13: 8MM, diagnosed prevalent cases of CD, N, both sexes, all ages, 2022
Figure 14: 8MM, diagnosed prevalent cases of CD by age, N, both sexes, 2022
Figure 15: 8MM, diagnosed prevalent cases of CD by sex, N, all ages, 2022
Figure 16: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages <18 years, 2022
Figure 17: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages >=18 years, 2022
Figure 18: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages <18 years, 2022
Figure 19: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages >=18 years, 2022
Figure 20: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages <18 years, 2022
Figure 21: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages >=18 years, 2022
Figure 22: Unmet needs and opportunities in CD
Figure 23: Overview of the development pipeline in CD
Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for CD in the 8MM during the forecast period
Figure 25: Competitive assessment of the late-stage biologics benchmarked against Humira
Figure 26: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
Figure 27: Analysis of the company portfolio gap in CD during the forecast period
Figure 28: Global (8MM) sales forecast by country for CD in 2022 and 2032
Figure 29: Sales forecast by class for CD in the US in 2022 and 2032
Figure 30: Sales forecast by class for CD in the 5EU in 2022 and 2032
Figure 31: Sales forecast by class for CD in Japan in 2022 and 2032
Figure 32: Sales forecast by class for CD in Canada in 2022 and 2032

Crohn's Disease: Eight-Market Drug Forecast and Market Analysis - Update (2025)

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Crohn's Disease: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures